Home/Pipeline/TILs Therapy

TILs Therapy

Solid Tumors

Pre-clinical/Early ClinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical/Early Clinical

Status

Active

Company

Essen Biotech

About Essen Biotech

Essen Biotech is a private, clinical-stage biotech firm pioneering personalized cellular and gene therapies for oncology and genetic disorders. Leveraging a broad platform encompassing CAR-T, TILs, NK cells, CRISPR, and MSC therapies, the company aims to address unmet medical needs through cutting-edge research. While its website suggests a global patient-facing service model, the core appears to be therapeutic development, likely positioning it as a pre-revenue entity advancing programs through clinical trials. Key challenges include navigating complex clinical pathways, securing sustained funding, and differentiating in the competitive cell therapy landscape.

View full company profile

Therapeutic Areas

Oncology Genetic Diseases Regenerative Medicine

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed